Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortin GlobalBOM:539287 -2.18%44 PB Ratio is 9.74 as of Aug. 23, 2026, which is 490% above its 10-year median of 1.65. GuruFocus rates BOM:539287 with a GF Score™ of 44/100 and a GF Value™ of ₹2.47 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 920 Drug Manufacturers companies, Ortin Global ranks worse than 92.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-23), Ortin Global's share price is ₹14.81. Ortin Global's Book Value per Share for the quarter that ended in Mar. 2026 was ₹1.52. Hence, Ortin Global's PB Ratio of today is 9.74.
The historical rank and industry rank for Ortin Global's PB Ratio or its related term are showing as below:
BOM:539287'
s PB Ratio Range Over the Past 10 Years
Min: 0.25 Med: 1.65 Max: 11.5
Current: 9.74
During the past 13 years, Ortin Global's highest PB Ratio was 11.50. The lowest was 0.25. And the median was 1.65.
BOM:539287's PB Ratio is ranked worse than 92.07% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.975
vs BOM:539287: 9.74
During the past 12 months, Ortin Global's average Book Value Per Share Growth Rate was -37.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -26.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ortin Global was 3.60% per year. The lowest was -51.50% per year. And the median was -13.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ortin Global PB Ratio Related Terms
Ortin Global PB Ratio Historical Data
* Premium members only.
The historical data trend for Ortin Global's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ortin Global's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Ortin Global's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ortin Global (BOM:539287) has a PB Ratio of 9.74 as of Aug. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ortin Global and its competitors. This is 490% above median its historical median of 1.65. Over the past decade, Ortin Global's PB Ratio has ranged from 0.25 to 11.50. According to the industry distribution chart, Ortin Global ranks #847 out of 920 companies in the Drug Manufacturers industry, placing it in the top 92.1%.
Is Ortin Global's PB Ratio too high?
Ortin Global's current PB Ratio of 9.74 is 490% above median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 11.50. The Drug Manufacturers industry median PB Ratio is 1.98. Ortin Global's value of 9.74 is 393.2% above this industry median. Based on the distribution chart, Ortin Global ranks #847 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ortin Global has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #847 out of 920 companies for PB Ratio. This places Ortin Global in the lower half of its industry. The industry median PB Ratio is 1.98. Ortin Global's value of 9.74 is 393.2% above this benchmark. Historically, Ortin Global's own PB Ratio has ranged from 0.25 to 11.50 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 1.98, Ortin Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ortin Global's current PB Ratio of 9.74 is 393.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current PB Ratio is 9.74, which is 490% above median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.47, compared to a current price of ₹14.81 — trading 499.6% above its estimated fair value. The current PB Ratio is 9.74, which is 490% above median its 10-year median of 1.65 and 393.2% above the Drug Manufacturers industry median of 1.98. Ortin Global's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current PB Ratio is 9.74 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (BOM:539287) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹14.81 is trading 499.6% above its estimated GF Value™ of ₹2.47.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for BOM:539287:
PB Ratio: 9.74 (490% above median its 10-year median of 1.65)
GF Value™: ₹2.47 vs. price of ₹14.81 (499.6% above fair value)
Industry Position: 393.2% above the Drug Manufacturers median (#847 of 920)
No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
44GF Score
Get the complete analysis for BOM:539287
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539287 has been successfully added to your 
